204 related articles for article (PubMed ID: 30312133)
21. Long-term outcome of 487 patients with early-stage extra-nodal marginal zone lymphoma.
Teckie S; Qi S; Chelius M; Lovie S; Hsu M; Noy A; Portlock C; Yahalom J
Ann Oncol; 2017 May; 28(5):1064-1069. PubMed ID: 28327924
[TBL] [Abstract][Full Text] [Related]
22. High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO.
Avivi I; Arcaini L; Ferretti VV; Boumendil A; Finel H; Milone G; Zaja F; Liliana D; Musso M; Didier B; Bachy E; Wattad M; Nicolas-Virelizier E; Gramatzki M; Bourhis JH; Caillot D; Haenel A; Held G; Thieblemont C; Jindra P; Pohlreich D; Guilhot F; Kroschinsky F; Wahlin B; Scheid C; Ifrah N; Berthou C; Dreger P; Montoto S; Conconi A
Br J Haematol; 2018 Sep; 182(6):807-815. PubMed ID: 29984825
[TBL] [Abstract][Full Text] [Related]
23. Splenic Marginal Zone Lymphoma With Histological Transformation to Hodgkin's Lymphoma.
Veeraballi S; Mirza N; Khawar Z; Shaaban H
Cureus; 2022 Jul; 14(7):e26738. PubMed ID: 35967131
[TBL] [Abstract][Full Text] [Related]
24. The highest prognostic impact of LDH among International Prognostic Indices (IPIs): an explorative study of five IPI factors among patients with DLBCL in the era of rituximab.
Park JH; Yoon DH; Kim DY; Kim S; Seo S; Jeong Y; Lee SW; Park CS; Huh J; Suh C
Ann Hematol; 2014 Oct; 93(10):1755-64. PubMed ID: 25027115
[TBL] [Abstract][Full Text] [Related]
25. Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study.
Oh SY; Kim WS; Kim JS; Kim SJ; Yoon DH; Yang DH; Lee WS; Kim HJ; Yhim HY; Jeong SH; Won JH; Lee S; Kong JH; Lim SN; Ji JH; Kwon KA; Lee GW; Lee JH; Lee HS; Shin HJ; Suh C
Cancer Commun (Lond); 2019 Oct; 39(1):58. PubMed ID: 31619290
[TBL] [Abstract][Full Text] [Related]
26. Real World Long-term Follow-up Experience with Yttrium-90 ibritumomab tiuxetan in Previously Untreated Patients with Low-Grade Follicular Lymphoma and Marginal Zone Lymphoma.
Alhaj Moustafa M; Peterson J; Hoppe BS; Jiang J; Wiseman GA; Witzig TE; Tun HW
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):618-625. PubMed ID: 35400611
[TBL] [Abstract][Full Text] [Related]
27. A prognostic index for extranodal marginal-zone lymphoma based on the mucosa-associated lymphoid tissue International Prognostic Index and serum β2-microglobulin levels.
Kim HD; Cho H; Jeong H; Bang K; Kim S; Lee K; Kang EH; Park JS; Park CS; Huh J; Ryu JS; Lee SW; Yoon DH; Oh SY; Suh C
Br J Haematol; 2021 Apr; 193(2):307-315. PubMed ID: 33216979
[TBL] [Abstract][Full Text] [Related]
28. Transformation and survival in marginal zone lymphoma: a Finnish nationwide population-based study.
Kalashnikov I; Tanskanen T; Viisanen L; Malila N; Jyrkkiö S; Leppä S
Blood Cancer J; 2023 Apr; 13(1):62. PubMed ID: 37185610
[TBL] [Abstract][Full Text] [Related]
29. Primary cutaneous blastic marginal zone lymphoma: A comprehensive clinical, light microscopic, phenotypic and cytogenetic appraisal.
Magro CM; Kalomeris T; Roberts A
Ann Diagn Pathol; 2023 Apr; 63():152101. PubMed ID: 36634549
[TBL] [Abstract][Full Text] [Related]
30. Value of total lesion glycolysis and cell-of-origin subtypes for prognostic stratification of diffuse large B-cell lymphoma patients.
Jiang C; Teng Y; Zheng Z; Zhou Z; Xu J
Quant Imaging Med Surg; 2021 Jun; 11(6):2509-2520. PubMed ID: 34079720
[TBL] [Abstract][Full Text] [Related]
31. Myeloid cell nuclear differentiation antigen is expressed in a subset of marginal zone lymphomas and is useful in the differential diagnosis with follicular lymphoma.
Metcalf RA; Monabati A; Vyas M; Roncador G; Gualco G; Bacchi CE; Younes SF; Natkunam Y; Freud AG
Hum Pathol; 2014 Aug; 45(8):1730-6. PubMed ID: 24925224
[TBL] [Abstract][Full Text] [Related]
32. Primary follicular and marginal-zone lymphoma of the breast: clinical features, prognostic factors and outcome: a study by the International Extranodal Lymphoma Study Group.
Martinelli G; Ryan G; Seymour JF; Nassi L; Steffanoni S; Alietti A; Calabrese L; Pruneri G; Santoro L; Kuper-Hommel M; Tsang R; Zinzani PL; Taghian A; Zucca E; Cavalli F
Ann Oncol; 2009 Dec; 20(12):1993-9. PubMed ID: 19570964
[TBL] [Abstract][Full Text] [Related]
33. Validation of the Marginal Zone Lymphoma International Prognostic Index.
Hong J; Cho J; Ko YH; Kim SJ; Kim WS
Ann Hematol; 2019 Feb; 98(2):457-464. PubMed ID: 30310985
[TBL] [Abstract][Full Text] [Related]
34. First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4.
Walewski J; Paszkiewicz-Kozik E; Michalski W; Rymkiewicz G; Szpila T; Butrym A; Giza A; Zaucha JM; Kalinka-Warzocha E; Wieczorkiewicz A; Zimowska-Curyło D; Knopińska-Posłuszny W; Tyczyńska A; Romejko-Jarosińska J; Dąbrowska-Iwanicka A; Gruszecka B; Jamrozek-Jedlińska M; Borawska A; Hołda W; Porowska A; Romanowicz A; Hellmann A; Stella-Hołowiecka B; Deptała A; Jurczak W
Br J Haematol; 2020 Mar; 188(6):898-906. PubMed ID: 31792945
[TBL] [Abstract][Full Text] [Related]
35. Cutaneous lymphoid hyperplasia and cutaneous marginal zone lymphoma: comparison of morphologic and immunophenotypic features.
Baldassano MF; Bailey EM; Ferry JA; Harris NL; Duncan LM
Am J Surg Pathol; 1999 Jan; 23(1):88-96. PubMed ID: 9888708
[TBL] [Abstract][Full Text] [Related]
36. Prognostic Value of Anemia and C-Reactive Protein Levels in Diffuse Large B-Cell Lymphoma.
Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):671-9. PubMed ID: 26361646
[TBL] [Abstract][Full Text] [Related]
37. [Marginal zone lymphoma with monoclonal immunoglobulin: three cases report and literatures review].
Wang F; Han X; Bai B; Wang C; Chen Y
Zhonghua Xue Ye Xue Za Zhi; 2016 Jan; 37(1):39-44. PubMed ID: 26876252
[TBL] [Abstract][Full Text] [Related]
38. Non-gastric marginal zone B cell lymphoma: clinicopathologic features and treatment results.
Gill H; Chim CS; Au WY; Loong F; Tse E; Leung AY; Kwong YL
Ann Hematol; 2011 Dec; 90(12):1399-407. PubMed ID: 21476016
[TBL] [Abstract][Full Text] [Related]
39. Relapsed or refractory nongastric marginal zone B-cell lymphoma: multicenter retrospective analysis of 92 cases.
Oh SY; Kim WS; Kim SJ; Kim JS; Kim SH; Lee DH; Won JH; Hwang IG; Kim MK; Lee SI; Kim JG; Yang DH; Kang HJ; Choi CW; Park J; Choi YJ; Kim HJ; Kwon JH; Suh C; Kim HJ
Am J Hematol; 2009 Dec; 84(12):826-9. PubMed ID: 19890833
[TBL] [Abstract][Full Text] [Related]
40. The clinical significance of increased large cells in marginal zone lymphoma.
Stueber T; Jaitly V; Moore EM
Hum Pathol; 2023 Nov; 141():130-138. PubMed ID: 37633532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
